Notably, AML patients harboring NPM1 mutation, who in many cases often have <1% normal CD34+ cells11, expressed significantly lower TMIGD2 (Supplementary Table 2), suggesting that TMIGD2 is specifically expressed on the malignant CD34+ cells. The gene discussed is TMIGD2; the disease is acute myeloid leukemia.